Firefly Neuroscience, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.3M
- Price
- $0.9102
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.01%
- Volume
- 78.1K
About
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.
Quick stats
Shares outstanding15.7M
Computed float14.9M
Float / shares94.9%
Cash runway (months)11.5
Key info
SectorTechnology
IndustrySoftware - Application
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000803578
Websitehttps://fireflyneuro.com
AI Summary
AI-generated1/26
minorbullishoperations update
Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform
Firefly Neuroscience provided a strategy update highlighting its commercially available Versus platform, a wireless dry-sensor EEG headset with interactive training software that has shipped more than 3,000 units and generates commercial revenue.
Versus allows users to control flight and driving simulations through real-time brainwave activity, positioning Firefly in the human-performance segment of the emerging non-invasive BCI market.
The company also reiterated its plan to build an EEG/ERP-based brain foundation model using its database of over 200,000 standardized scans, the FDA 510(k)-cleared Evoke platform, and NVIDIA GPU acceleration, citing Neuralink and Merge Labs as signs of the sector's momentum.
Red flags
- No new financial figures or revenue disclosed; long-dated AI foundation model goals remain aspirational and subject to validation